APA (7th ed.) Citation

JS, H., S, J., M, W., Y, M., A, N., J, B., . . . JS, W. (2024). Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients. Frontiers in immunology, 15, 1482715. https://doi.org/10.3389/fimmu.2024.1482715

Chicago Style (17th ed.) Citation

JS, Heitmann, et al. "Warehouse-based, Immunopeptidome-guided Design of Personalised Peptide Vaccines Shows Feasibility in Clinical Trial Evaluation in CLL Patients." Frontiers in Immunology 15 (2024): 1482715. https://doi.org/10.3389/fimmu.2024.1482715.

MLA (9th ed.) Citation

JS, Heitmann, et al. "Warehouse-based, Immunopeptidome-guided Design of Personalised Peptide Vaccines Shows Feasibility in Clinical Trial Evaluation in CLL Patients." Frontiers in Immunology, vol. 15, 2024, p. 1482715, https://doi.org/10.3389/fimmu.2024.1482715.